Deroy & Devereaux Private Investment Counsel Inc. Grows Stock Holdings in STERIS plc (NYSE:STE)

Deroy & Devereaux Private Investment Counsel Inc. raised its position in shares of STERIS plc (NYSE:STE) by 0.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,250 shares of the medical equipment provider’s stock after buying an additional 140 shares during the quarter. Deroy & Devereaux Private Investment Counsel Inc.’s holdings in STERIS were worth $4,184,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. West Coast Financial LLC lifted its position in shares of STERIS by 2.8% during the third quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock valued at $398,000 after buying an additional 45 shares during the last quarter. Taylor Frigon Capital Management LLC lifted its position in shares of STERIS by 0.8% during the second quarter. Taylor Frigon Capital Management LLC now owns 6,175 shares of the medical equipment provider’s stock valued at $1,356,000 after buying an additional 46 shares during the last quarter. J.Safra Asset Management Corp lifted its position in shares of STERIS by 77.9% during the first quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 53 shares during the last quarter. Mather Group LLC. lifted its position in shares of STERIS by 7.6% during the second quarter. Mather Group LLC. now owns 763 shares of the medical equipment provider’s stock valued at $172,000 after buying an additional 54 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in shares of STERIS by 16.5% during the first quarter. EverSource Wealth Advisors LLC now owns 402 shares of the medical equipment provider’s stock valued at $82,000 after buying an additional 57 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares in the company, valued at approximately $10,603,710. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other STERIS news, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares of the company’s stock, valued at $139,493.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

STE has been the topic of several recent analyst reports. KeyCorp upped their price objective on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. Stephens reaffirmed an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.00.

STERIS Trading Down 1.2 %

Shares of NYSE:STE opened at $221.80 on Friday. STERIS plc has a 1 year low of $195.47 and a 1 year high of $248.24. The firm has a market capitalization of $21.87 billion, a price-to-earnings ratio of 55.04 and a beta of 0.84. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49. The business’s 50 day moving average price is $233.94 and its 200-day moving average price is $226.68.

STERIS (NYSE:STE) last announced its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.16. The company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The firm’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter last year, the firm posted $2.00 EPS. On average, equities research analysts forecast that STERIS plc will post 9.02 earnings per share for the current fiscal year.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.